NCT02626065 (PAIR) is a Phase 4 clinical trial of blood sampling in Metastatic Melanoma, sponsored by Hospices Civils de Lyon.

Who is sponsoring NCT02626065?

NCT02626065 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT02626065?

Interventions in NCT02626065: blood sampling, Nivolumab.

What condition does NCT02626065 study?

NCT02626065 studies Metastatic Melanoma.

Is NCT02626065 still recruiting?

NCT02626065 is currently completed. Last updated 15 September 2025.

Last reviewed 2025-09-15 · How we verify

NCT02626065: PAIR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies

Completed Phase 4 Last updated 15 September 2025

What this trial tests

Phase 4 trial testing blood sampling in Metastatic Melanoma in 32 participants. Completed in 28 December 2017.

Timeline

23 April 2015

Primary endpoint
28 December 2017

28 December 2017

Quick facts

Lead sponsor	Hospices Civils de Lyon
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	32
Start date	23 April 2015
Primary completion	28 December 2017
Estimated completion	28 December 2017
Sites	1 location across France

Drugs / interventions tested

blood sampling — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Metastatic Melanoma — all drugs for Metastatic Melanoma →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Metastatic Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open mono-centric prospective non-randomized study in patients with metastatic melanoma treated with Anti-PD1 monoclonal antibodies (Nivolumab). The aim of the study is to identify the immune cells modulations differences between patients who present a complete, partial or stable response and patients who have non-response to the therapy in order to establish an improving response rate strategy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.
Perier-Muzet M, Gatt E, Péron J, Falandry C, et al · · 2018 · cited 50× · PMID 29214290 · DOI 10.1001/jamadermatol.2017.4584
Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.
Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, et al · · 2023 · cited 36× · PMID 35709010 · DOI 10.2337/db21-1172
Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients.
Dalle S, Verronese E, N'Kodia A, Bardin C, et al · · 2024 · cited 4× · PMID 38939518 · DOI 10.1080/2162402x.2024.2372118

Verify or expand the search:

Other trials of blood sampling

Trials testing the same drug.

NCT07467109 — A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of · not yet recruiting
NCT07347613 — Long-term Follow-up of Diabetic Patients From the GLUTADIAB Study · not yet recruiting
NCT07472387 — Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas · NA · not yet recruiting
NCT07477769 — Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD) · not yet recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other recruiting trials for Metastatic Melanoma

Currently open trials in the same condition.

NCT06066138 — A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · Phase 1 · recruiting
NCT07237100 — Mirdametinib in Patients With Advanced NF1-mutant Melanoma · Phase 2 · recruiting
NCT07086105 — A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma · Phase 1 · recruiting
NCT07112170 — Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma · NA · recruiting
NCT06488365 — In Vivo Liquid Biopsy of Melanoma (Cytophone) · NA · recruiting

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02626065 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 15 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02626065.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing